Exelixis, Inc. (EXEL) Analysts See $0.19 EPS

October 14, 2018 - By olga

Exelixis, Inc. (NASDAQ:EXEL) LogoInvestors sentiment increased to 1.28 in 2018 Q2. Its up 0.12, from 1.16 in 2018Q1. It increased, as 41 investors sold Exelixis, Inc. shares while 68 reduced holdings. 55 funds opened positions while 85 raised stakes. 234.21 million shares or 3.66% more from 225.93 million shares in 2018Q1 were reported.
Great West Life Assurance Can owns 31,890 shares. Consonance Capital Management L P holds 4.45% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL) for 3.21 million shares. Cambridge Advsrs invested 0% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Gradient Investments Ltd holds 400 shares. Amundi Pioneer Asset reported 0% in Exelixis, Inc. (NASDAQ:EXEL). Kistler holds 200 shares or 0% of its portfolio. Glenmede Communications Na has invested 0% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Cap Impact Advsrs Limited Liability has invested 0.34% in Exelixis, Inc. (NASDAQ:EXEL). Macquarie Ltd has 3.55M shares for 0.13% of their portfolio. Wells Fargo Mn has 0.02% invested in Exelixis, Inc. (NASDAQ:EXEL). 3.74M were reported by Voya Investment Management Lc. Tealwood Asset Mgmt, a Minnesota-based fund reported 157,707 shares. Bb Biotech Ag invested in 0.66% or 1.06 million shares. Piermont Cap holds 33,630 shares or 0.22% of its portfolio. 9,878 were reported by Washington Financial Bank.

Since April 11, 2018, it had 0 insider buys, and 18 selling transactions for $14.98 million activity. $1.07M worth of Exelixis, Inc. (NASDAQ:EXEL) shares were sold by WILLSEY LANCE. Schwab Gisela also sold $468,000 worth of Exelixis, Inc. (NASDAQ:EXEL) on Friday, June 1. The insider Hessekiel Jeffrey sold $447,200. MARCHESI VINCENT T had sold 15,000 shares worth $285,450. The insider Garber Alan M sold 15,000 shares worth $303,750. COHEN CHARLES sold $321,300 worth of stock or 15,000 shares.

Analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report $0.19 EPS on November, 7.They anticipate $0.07 EPS change or 26.92 % from last quarter’s $0.26 EPS. EXEL’s profit would be $56.63 million giving it 21.37 P/E if the $0.19 EPS is correct. After having $0.28 EPS previously, Exelixis, Inc.’s analysts see -32.14 % EPS growth. The stock increased 1.88% or $0.3 during the last trading session, reaching $16.24. About 2.51M shares traded. Exelixis, Inc. (NASDAQ:EXEL) has declined 38.03% since October 14, 2017 and is downtrending. It has underperformed by 53.65% the S&P500.

Exelixis, Inc. (NASDAQ:EXEL) Ratings Coverage

Among 3 analysts covering Exelixis (NASDAQ:EXEL), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Exelixis had 4 analyst reports since May 3, 2018 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, May 3 by Stifel Nicolaus. Stifel Nicolaus maintained it with “Hold” rating and $25 target in Wednesday, August 1 report.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $4.84 billion. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 15.75 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.

Another recent and important Exelixis, Inc. (NASDAQ:EXEL) news was published by Seekingalpha.com which published an article titled: “Exelixis: An Updated View” on September 14, 2018.

Exelixis, Inc. (NASDAQ:EXEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: